Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 3 5Phase NA 2Phase 2/3 2Phase 1/2 2Phase 1 1

Status

Completed 19Terminated 8Unknown 4Withdrawn 3Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 1Hematologic Neoplasms 1Bronchiolitis Obliterans Syndrome 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × Busulfan × Clear all
NCT06158828 2026-05-05

ABCD-NK

Washington University School of Medicine

Phase 1/2 Recruiting
68 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05327023 2026-04-28

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Recruiting
430 enrolled
Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡